About Us
Home > About Us
Huarong (Guangdong)Pharmaceutical Co., Ltd.
Pharmaceutical Raw Material Research and Developme
Huarong (Guangdong) Pharmaceutical Co., Ltd. (established in 2023) is a powerful enterprise integrating scientific research, production and supply, and has in-depth cooperation with Lao United Pharmaceutical. The company has an exclusive R&D team, its own production park and two production bases in Guangzhou Huangpu and Shaoguan Nanxiong, covering a total area of 80 acres, a construction area of more than 30,000 square meters, more than 100 employees, and a total investment of 200 million yuan. Focusing on the R&D and mass production of amino acids and peptides, with an annual production capacity of 4,000 tons and an estimated annual output value of 1 billion yuan, it is a leading intelligent biosynthetic API production base in China to ensure quality with full-process quality control and serve customers in many countries around the world.

The company has two R&D centers in Guangdong and Jiangxi, and has established in-depth cooperative relations with Hunan University, South China Agricultural University, Nanchang University, Liaocheng University, Jiangxi University of Traditional Chinese Medicine and other universities. At present, it has built a complete experimental platform such as synthesis laboratory, microbiology laboratory, fermentation laboratory, and quality analysis laboratory, and is equipped with an exclusive technology center responsible for technology transformation and large-scale production.
The R&D team has strong strength, and now has 3 senior engineers, 5 personnel with master's degree or above, and 20 personnel with bachelor's degree or above. The laboratory is equipped with various advanced synthesis, biological and testing equipment, including 5 HPLC chromatographs, 2 gas chromatographs, 1 gram-level preparative chromatograph, 1 100-gram preparative chromatograph, 1 peptide solid-phase synthesizer, 3 5-liter fermenters, 3 100-liter fermenters, 3 biological safety cabinets, 3 oscillating incubators, 1 freeze dryer, etc.
  • 53000
    Land area
  • 30000
    Floor area
  • 200million
    Invest in RMB
  • 4000ton/year
    Annual production capacity
  • 973million RMB/year
    Annual income
  • 150+
    Employee
Case Show
R&D team
  • Gao Libo

    With extensive professional experience, he has served as a production and technology executive in state-owned enterprises and listed companies, accumulating diverse industry insights. Proficient in technology, equipment, and EHS/GMP management systems of API factories; possesses experience in multiple construction projects. Graduated from Hebei Light Chemical Industry College with a bachelor's degree in Chemical Engineering and Technology.

  • Dr. Li Dingzhong

    Born in Liuyang, Hunan, with over a decade of experience in pharmaceutical R&D, he possesses extensive expertise in drug process development. He earned his Ph.D. in Chemistry from Hunan University in 2022. He has held positions as Pharmaceutical R&D Manager at Wuchan Zhongda Jiangsu Keben Pharmaceutical and as Assistant Technical R&D Director at Hunan Daoshi Pharmaceutical Technology Co., Ltd. Currently, he serves as the Technical Director at Guangzhou Huagan Pharmaceutical Development Co., Ltd.

  • Zeng Fanrong

    A native of Suichuan, Jiangxi, graduated from Nanchang University with a master's degree in organic chemistry, and a senior engineer in organic chemical engineering. In 2012, he won the first prize of the Ganzhou Science and Technology Progress Award, and in 2023, he was recognized as a senior talent (Class E) in Hangzhou, with rich experience in API process research and development and synthetic antigen development. Published 6 authorized patents. During his tenure as the director of the API workshop and the manager of the technology transfer department of Qingfeng Pharmaceutical Group, he led the team to organize and participate in the technical research of the API entecavir, and completed the marketing application of entecavir, the production site inspection and GMP certification of entecavir. At the same time, he also organized and participated in a number of major projects of the group, such as Xiyanping injection, methylcobalamin, lacosamide and other technical research and breakthroughs. In Hangzhou LONGi Biotechnology Co., Ltd., he was responsible for antigen synthesis and research and development, during which he developed 7 new antigens.

  • Luo Rilang

    He has mastered peptide solid-phase synthesis technology and semiconductor industry technology, and has worked as a technology development engineer and researcher in a leading listed company of peptide drugs, and is currently the technical director of peptide research and development of Huagan Pharmaceutical. His past work has involved peptide drug API pilot process development, process optimization and scale-up transfer research, and process verification and optimization of peptide microarray chips for in-situ synthesis and preparation of peptide microarray chips using semiconductor automation industrial technology, and automated production line design. He has rich experience in the development of GLP-1 Ras drug semi-synthesis and full synthesis preparation process and the in-situ synthesis and automated production of peptide microarray chips. He has applied for a number of patents, 3 domestic patents and 1 international patent authorization.


  • Zhang Xue

    Graduated with a master's degree in Bioengineering from Liaocheng University, mainly responsible for research on fermentation processes of novel biological enzyme preparations.

  • Wang Longshu

    Master's degree in Organic Chemistry, graduated with a bachelor's degree from Sichuan University, and pursued a master's degree at Sun Yat-sen University under Academician Chen Xinzi and Professor Qiu Liqin, focusing on asymmetric synthesis and total synthesis research. Formerly worked at Guangzhou Pharmaceutical Group and Livzon Pharmaceutical Group, holding positions such as R&D Supervisor, Project Manager, and Technical Department Manager, with over ten years of experience in pharmaceutical research and project management. Skilled in drug synthesis, process improvement, and generic drug applications, he has led multiple API and formulation projects covering cephalosporins, anti-cancer drugs, reproductive system drugs, and innovative veterinary medicines, with some products having received approval and been commercialized. He holds five authorized patents, won the Guangdong Science and Technology Achievement Promotion Award in 2022, and was selected for the Guangdong Provincial Science and Technology Department's expert advisory database. Currently, he serves as the Head of the Synthesis Department at Huagan Pharmaceuticals, responsible for the synthesis R&D and industrialization of projects including novel antibacterial drugs and intermediates, peptide drugs, and high-end antibacterial agents.

  • Huang Jialiang

    Graduated from Guangdong Medical University. Currently working as a bio-research and development engineer at Huagan Pharmaceutical, mainly responsible for strain construction, protein purification, and formulation process development.

  • Ma Peng

    Bachelor's degree in Chemical Engineering and Technology. He has extensive work experience in the field of chemistry and chemical engineering, focusing on organic synthesis and process scale-up. He has previously worked at well-known CDMO companies such as WuXi AppTec and Pharmaron, serving as an assistant researcher responsible for experimental design and implementation, data analysis and process optimization, pilot testing, and process verification. He is currently a synthetic R&D engineer at Huagan Pharmaceuticals, responsible for and involved in the lab-scale development and process scale-up of APIs and intermediates, cosmetic ingredients, and flavors and fragrances related to the company's synthesis projects.

  • Song Li

    Master of Medicine from Southern Medical University. During the master's program, the research focused on the design, synthesis, and antibacterial activity of antimicrobial peptides and small molecule compounds, and published an SCI paper in the international top journal Journal of Medicinal Chemistry. Currently working as a peptide synthesis engineer at Huagan Pharmaceutical, with work involving the development and optimization of synthesis and purification processes for compounds such as semaglutide, ritaterlutide, VC-ethyl ether, and the herbicide fluazinam hydroxamate.

  • Luo Jing

    I have a bachelor's degree in Biomedical Engineering from Jiangxi University of Traditional Chinese Medicine. I am currently working as an Assistant Researcher at Huagan Pharmaceuticals, responsible for participating in the laboratory's daily OOS/OOT investigations, equipment calibration, as well as drafting and revising SOPs, while also handling routine project testing tasks.

合作专家与高校
  • Gong Fuchun

    He holds a postgraduate degree from the School of Chemistry and Chemical Engineering of Hunan University, a doctorate in science, and a professor and graduate supervisor of the School of Chemistry and Chemical Engineering of Changsha University of Science and Technology. He has presided over and participated in the completion of a total of 16 national/provincial and ministerial projects, and published more than 110 high-level research papers (95 are included in SCI). He presided over and completed 8 school-enterprise cooperation research projects. In the project of "Research on Efficient Synthesis Technology of Artemether", a new process of etherification reaction based on feedback regulation mechanism was developed, which increased the product ratio of -and-artemether from about 55/45 to 98/2, breaking through the bottleneck of difficult product separation and low yield caused by the use of traditional catalysts. A new semi-synthesis process of vinpocetine based on the "one-pot method" reaction was developed, so that the vinblastine dehydration and esterification reaction was carried out in one pot, and the efficient synthesis of vinpocetine was realized. These two projects alone have created a total of 2.5 billion yuan in economic benefits for enterprises. In addition, new synthesis processes and technologies for drug intermediates such as benefantrine, galantamine, yellow vine and guanine have been developed for related enterprises.

  • Qiu Renhua

    Professor, Doctor of Engineering, Doctoral Supervisor of the School of Chemistry and Chemical Engineering of Hunan University, Member of the Hunan Provincial Committee of the Peasants' and Workers' Party, Director of the Youth Working Committee, Deputy Director of the Grassroots Committee of Hunan University. At present, more than 90 SCI research papers have been published. More than 50 authorized invention patents (2 of which have been transferred to Jinyu New Materials to complete industrialization, and 3 to the listed company Auriite Pharmaceutical); In 2016, he was selected into the Huxiang Young Talents Support Program, and won the first prize of Hunan Natural Science Award (5th completer, 2024), the first prize of Hunan Natural Science Award (2nd completer, 2015), Hunan Petrochemical Outstanding Engineer (2016), Hunan Province Outstanding Doctoral Dissertation Award (2014), Hunan Youth Chemistry and Chemical Engineering Award (2012), Japan Association for the Promotion of Science JSPS Fellowship (2012), and academic conference excellent poster award more than 10 times. He has presided over more than 20 projects commissioned by the National Natural Science Foundation of China (4 of which have been completed) and other national, provincial, municipal and enterprise commissioned projects; He has served as a reviewer for more than 20 international journals and a project reviewer of the National Natural Science Foundation of China and the Hong Kong Government Research Fund.

  • Wu Lijun

    He is a doctor of science from Hunan University, a postdoctoral fellow at Peking University, and a master's tutor at Central South University of Forestry and Technology, mainly engaged in scientific research in organic synthesis chemistry, drug synthesis, high-end fine chemical synthesis and green chemical industry. At present, he has presided over and participated in more than ten projects such as the National Self-Science Fund, the China Postdoctoral Fund, and the Provincial Self-Science Fund. Chem. Int. Ed., Chem. Sci., Org. Lett. and Chem. Commun. and other international high-level journals; Three national invention patents were authorized. He has presided over 3 school-enterprise cooperation projects, including the "Green Process Research on Valine Synthesis of Lactam" project, which has created economic benefits of more than 2 million yuan for related enterprises.

  • Lei jian

    He holds a postgraduate degree from the School of Chemistry and Chemical Engineering of Hunan University, a doctorate in engineering, and a lecturer and graduate supervisor at the School of Pharmacy of Gannan Medical University. He is mainly engaged in scientific research related to medicinal chemistry and synthetic chemistry. He has presided over and participated in the completion of a total of 6 national/provincial and ministerial projects, and published more than 20 SCI papers.


  • Zhu Longzhi

    A native of Hengyang, Hunan Province, he has a postgraduate degree from the School of Chemistry and Chemical Engineering of Hunan University, a doctorate in science, and a lecturer and graduate tutor of Hunan Institute of Technology. He has presided over and participated in the completion of a total of 3 national/provincial and ministerial projects, and published more than 20 high-level research papers as corresponding authors (4 papers in the first district of the Chinese Academy of Sciences). Applied for a number of patents.

  • Long Jin Guo

    Graduated from Shanghai Jiao Tong University with a Ph.D. in Science, postdoctoral fellow and assistant researcher at the School of Chemistry and Chemical Engineering of Hunan University, associate professor and graduate supervisor of Hangzhou Normal University. He is mainly engaged in research in the fields of asymmetric catalysis, carbon one chemistry and drug process design. The corresponding author is published in Angew. Chem. Int. Ed.、ACS. Catal. Org. Lett. and other journals, and 5 invention patents were authorized. He has presided over the National Natural Science Youth Fund, the Hunan Natural Science Youth Fund, and the China Postdoctoral Fund.

  • Office 801, Office Building, No. 1 Development Avenue, Nanzhong Industrial Transfer Park, Shaoguan City, Guangdong Province
  • +86 19925801629
  • 18507905903